胱胺酸尿症治疗市场－全球产业规模、份额、趋势、机会和预测，按类型、药物、给药途径、配销通路、地区和竞争格局划分，2020-2030年预测

2024年全球胱胺酸尿症治疗市场价值为1.6亿美元，预计2030年将以4.70%的复合年增长率成长至2.1077亿美元。全球胱胺酸尿症治疗市场涵盖旨在预防和控制泌尿道胱胺酸结石復发的药物和医疗干预措施，胱胺酸尿症是一种罕见的遗传性疾病。

主要市场驱动因素

新型治疗药物和治疗方式的进步显着推动了全球胱胺酸尿症治疗市场的发展，带来了更有效、耐受性更好的治疗选择。传统的胱胺酸尿症治疗方法往往副作用较大，导致患者依从性差，容易出现结石復发。

主要市场挑战

胱胺酸尿症本身的罕见性对其治疗市场的成长构成了重大挑战。极少的患者群体直接限制了对新型治疗方法进行广泛研究和开发的商业可行性。

主要市场趋势

一个显着的趋势是强调个人化医疗方法。这种方法是指根据患者的个别情况（通常基于特定的基因突变或疾病特征）量身定制治疗方案，以提高疗效并最大限度地减少不良反应。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球胱胺酸尿症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（胱胺酸尿症 1 型、胱胺酸尿症 2 型、胱胺酸尿症 3 型）
  • 依药物分类（硫普罗宁、青霉胺、卡托普利、其他）
  • 依给药途径（口服、注射）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美胱胺酸尿症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲胱胺酸尿症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区胱胺酸尿症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲胱胺酸尿症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲胱胺酸尿症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球胱胺酸尿症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Travere Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd
• Advicenne SACA
• Teva Pharmaceutical Industries Ltd
• ANI Pharmaceuticals, Inc
• Viatris Inc
• Advanz Pharma Corp
• Camber Pharmaceuticals, Inc
• Bausch Health Companies Inc
• Synact Pharma AB

第十六章：策略建议

第17章调查会社について・免责事项

The Global Cystinuria treatment Market, valued at USD 160.00 Million in 2024, is projected to experience a CAGR of 4.70% to reach USD 210.77 Million by 2030. The Global Cystinuria treatment market encompasses pharmaceutical and medical interventions designed to prevent and manage the recurrence of cystine calculi in the urinary tract, a manifestation of the rare genetic disorder, cystinuria.

Key Market Drivers

Advancements in Novel Therapeutic Agents and Treatment Modalities significantly propel the Global Cystinuria treatment market by introducing more effective and better tolerated options. Traditional treatments for this rare genetic disorder often presented considerable side effects, contributing to suboptimal patient adherence and persistent stone recurrence. The development of new compounds, drug classes, and innovative delivery methods promises improved outcomes and enhances patient quality of life. Progress in understanding disease pathophysiology facilitates targeted interventions.

Key Market Challenges

The inherent rarity of cystinuria presents a significant challenge to the growth of its treatment market. The extremely small patient population directly limits the commercial viability for extensive research and development into novel therapeutic approaches. Pharmaceutical companies encounter considerable financial risks when investing in treatments for conditions with such limited market potential, as the prospects of recouping substantial R&D costs are diminished. This specialized nature of therapies for rare disorders, coupled with the small patient pool, inevitably contributes to higher per-patient treatment expenses. Such elevated costs can severely restrict global accessibility and adoption, particularly within healthcare systems operating under constrained budgets, thereby hindering broader market penetration.

Key Market Trends

A prominent trend is the Emphasis on Personalized Medicine Approaches. This involves tailoring treatment regimens to individual patient profiles, often based on specific genetic mutations or disease characteristics, to enhance efficacy and minimize adverse effects. This approach marks a departure from conventional generalized treatments, promising more precise interventions for a rare genetic disorder like cystinuria.

Key Market Players

• Travere Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd
• Advicenne SACA
• Teva Pharmaceutical Industries Ltd
• ANI Pharmaceuticals, Inc
• Viatris Inc
• Advanz Pharma Corp
• Camber Pharmaceuticals, Inc
• Bausch Health Companies Inc
• Synact Pharma AB

Report Scope:

In this report, the Global Cystinuria treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cystinuria treatment Market, By Type:

• Cystinuria Type 1
• Cystinuria Type 2
• Cystinuria Type 3

Cystinuria treatment Market, By Drugs:

• Tiopronin
• Penicillamine
• Captopril
• Others

Cystinuria treatment Market, By Route of Administration:

• Oral
• Injectables

Cystinuria treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cystinuria treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cystinuria treatment Market.

Available Customizations:

Global Cystinuria treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cystinuria treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Cystinuria Type 1, Cystinuria Type 2, Cystinuria Type 3)
  • 5.2.2. By Drugs (Tiopronin, Penicillamine, Captopril, Others)
  • 5.2.3. By Route of Administration (Oral, Injectables)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Cystinuria treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drugs
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cystinuria treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drugs
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Cystinuria treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drugs
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Cystinuria treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drugs
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Cystinuria treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drugs
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cystinuria treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drugs
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Cystinuria treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drugs
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Cystinuria treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drugs
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Cystinuria treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drugs
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Cystinuria treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drugs
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Cystinuria treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drugs
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cystinuria treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drugs
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Cystinuria treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drugs
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Cystinuria treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drugs
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Cystinuria treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drugs
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Cystinuria treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drugs
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Cystinuria treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drugs
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cystinuria treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drugs
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Cystinuria treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drugs
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Cystinuria treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drugs
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Cystinuria treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drugs
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cystinuria treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drugs
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Cystinuria treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drugs
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Cystinuria treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drugs
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cystinuria treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Travere Therapeutics, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Dr. Reddy's Laboratories Ltd
• 15.3. Advicenne SACA
• 15.4. Teva Pharmaceutical Industries Ltd
• 15.5. ANI Pharmaceuticals, Inc
• 15.6. Viatris Inc
• 15.7. Advanz Pharma Corp
• 15.8. Camber Pharmaceuticals, Inc
• 15.9. Bausch Health Companies Inc
• 15.10. Synact Pharma AB

16. Strategic Recommendations

17. About Us & Disclaimer